Results 211 to 220 of about 198,039 (308)

Pembrolizumab in programmed death ligand 1-positive endometrial cancer [PDF]

, 2017
BENEDETTI PANICI, Pierluigi, Tomao, Federica, Tomao, Silverio   +2 more
core   +1 more source

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis

Cancer Science, EarlyView.
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, Kenichi Watanabe, Toru Mukohara, Yibin Kong, Masashi Shimura, Francisco Beca, Peter Schmid, Hiroji Iwata   +16 more
wiley   +1 more source

Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report. [PDF]

IJU Case Rep
Kanemoto S, Yamamoto S, Hino K, Tsuboi K, Kakizaki M, Nishiyama Y, Fukata S, Arata R, Inoue K, Ono N.   +9 more
europepmc   +1 more source

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng, Jennette Gruchy, Ariel Burns, Richard Langley, Jason Williams, Ryan DeCoste   +5 more
wiley   +1 more source

Stage I placental site trophoblastic tumor with complete response after pembrolizumab. [PDF]

Gynecol Oncol Rep
Descargues P, Eiriksson LR, Rousset P, Msika A, You B, Trecourt A, Massardier J, Hajri T, Borghese B, Golfier F, Bolze PA, Alexandre J.   +11 more
europepmc   +1 more source

Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response

Iris van ’t Erve, Isabelle Blanchard, Judy Y. Pagtama, Alison J. Holmes Tisch, Ash A. Alizadeh, Kavitha Ramchandran, Heather A. Wakelee, Sukhmani K. Padda, Maximilian Diehn, Joel W. Neal   +9 more
openalex   +1 more source

Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples

Cytopathology, EarlyView.
The study evaluates the use of residual liquid‐based cytology (LBC) samples from pancreatic ductal adenocarcinoma (PDAC) for molecular analysis. It shows that LBC samples preserve nucleic acid quality and remain suitable for next‐generation sequencing (NGS) and MSI testing even after prolonged storage, underscoring their value when other samples are ...
Raquel Antón‐Peñalver, María Ortega, Jose Francisco González‐Muñoz, Desamparados Compañ, Constanza Galindo, Clara Arnau, Marisol Huerta, Valentina Gambardella, Desamparados Roda, Rosana Villagrasa, Vicente Sanchiz, Andrés Peña, Elena Muñoz‐Forner, Isabel Mora Oliver, Luis Sabater, Andrés Cervantes, Antonio Ferrández, Clara Alfaro‐Cervelló   +17 more
wiley   +1 more source

LEAP-008: pembrolizumab plus lenvatinib after immunotherapy in non-small cell lung cancer. [PDF]

J Thorac Dis
Fukuda K.
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

Complete Pathological Response to Neoadjuvant Cisplatin, Etoposide, and Pembrolizumab in Small Cell Breast Carcinoma: A Case Report and Review of the Literature. [PDF]

Case Rep Oncol
Soh HT, Sood S, Ho F, Mok K, Chua W, Nindra U.   +5 more
europepmc   +1 more source